AGAMENON-SEOM Study: Spanish Registry of Esophagogastric Cancer
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 10,000
- 试验地点
- 38
- 主要终点
- Diagnostic and therapeutic approach
研究概览
简要总结
This study aims to development of a database through a web page for epidemiological and clinical research purposes that is accessible to members of the AGAMENON - SEOM group that guarantees a rigorous collection, exploitation and analysis of the data and information contained, increases the knowledge of esophageal and stomach cancer in order to optimize the management, treatment and evolution of patients, the possibility of comparing variables with those of other series or groups, and promotes the quality of scientific publications.
详细描述
Patient data will be collected from medical records retrospectively.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 100 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patient (≥18 years) diagnosed with carcinoma of the esophagus, gastroesophageal junction and stomach, including all histologic subtypes, with or without erbB2 overexpression (and tumors in which this data is unknown).
- •Follow-up of at least 3 months with clinical information during this period, exempting patients with early death from any cause.
排除标准
- •A patient for whom, for whatever reason, the information necessary to complete the database cannot be known or obtained.
研究组 & 干预措施
Cohort 1
Resectable non-advanced cancer
干预措施: Surgery (Procedure)
Cohort 1
Resectable non-advanced cancer
干预措施: Chemotherapy, anti-targeted agents and immunotherapy (Drug)
Cohort 1
Resectable non-advanced cancer
干预措施: Radiotherapy (Radiation)
Cohort 2
Unresectable advanced cancer
干预措施: Surgery (Procedure)
Cohort 2
Unresectable advanced cancer
干预措施: Chemotherapy, anti-targeted agents and immunotherapy (Drug)
Cohort 2
Unresectable advanced cancer
干预措施: Radiotherapy (Radiation)
结局指标
主要结局
Diagnostic and therapeutic approach
时间窗: Up to 12 months
To evaluate survival (time in months) according to treatment of esophagogastric cancer in all stages, patients, and contexts.
次要结局
- Epidemiological profiles(Up to 12 months)
- Risk factors(Up to 12 months)
- Clinical and diagnostic approach(Up to 12 months)
- Validate and compare prognostic models(Up to 12 months)
- Create and validate a predictive model(Up to 12 months)
- Pathological features(Up to 12 months)
- Prognostic factors(Up to 12 months)
- Treatments adjusted to prognostic variables(Up to 12 months)